Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors.

Pruett, Jacob E; Romero, Damian G; Yanes Cardozo, Licy L

Pruett, Jacob E; Romero, Damian G; Yanes Cardozo, Licy L.

Affiliation

Pruett JE; Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, United States.
Romero DG; Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, United States.
Yanes Cardozo LL; Mississippi Center of Excellence in Perinatal Research, University of Mississippi Medical Center, Jackson, MS, United States.

Front Endocrinol (Lausanne) ; 14: 951099, 2023.

Article in En | MEDLINE | ID: mdl-36875461

Subject(s)

Obesity; Polycystic Ovary Syndrome; Sodium-Glucose Transporter 2 Inhibitors; Female; Humans; Diabetes Mellitus, Type 2; Hypertension; Polycystic Ovary Syndrome/drug therapy; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

Key words

SGLT 2 inhibitors; cardiometabolic complications; hypertension; insulin resistance; mitochondrial dysfunction; obesity; polycystic ovary syndrome (PCOS); women's health

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polycystic Ovary Syndrome / Sodium-Glucose Transporter 2 Inhibitors / Obesity Type of study: Risk_factors_studies Limits: Female / Humans Language: En Journal: Front Endocrinol (Lausanne) Year: 2023 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google